Automated and Closed Cell Therapy Processing Systems Market Size, Share and Growth Outlook, 2026

Automated and Closed Cell Therapy Processing Systems Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Automated and Closed Cell Therapy Processing Systems Market size is forecast to increase from $2.34 Billion in 2026 to $9.22 Billion in 2034 at a CAGR of 18.7% between 2026 and 2034.

The Automated and Closed Cell Therapy Processing Systems market report provides detailed analysis and outlook of Automated and Closed Cell Therapy Processing Systems segments including By Workflow (Apheresis, Separation, Expansion, Fill-Finish, Cryopreservation), By Product Type (Stem Cell Therapy Systems, Non-Stem Cell Therapy Systems), By Scale (Pre-commercial Scale, Commercial Scale), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Academic Medical Centers, Contract Development & Manufacturing Organizations) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Automated and Closed Cell Therapy Processing Systems Industry Overview

Automation and Closed-System Manufacturing Transforming Cell Therapy Production

The automated and closed cell therapy processing systems industry is rapidly advancing as developers seek scalable, reproducible, and contamination-resistant manufacturing solutions for cell and gene therapies. A major catalyst for innovation is the growing regulatory and governmental support for decentralized biomanufacturing models. The Advanced Research Projects Agency for Health launched a targeted funding initiative focused on accelerating next-generation manufacturing approaches for cell and gene therapies. The program specifically promotes decentralized production systems supported by automated quality assurance processes. Simultaneously, regulatory updates from the U.S. Food and Drug Administration have expanded flexibility for cell and gene therapy manufacturers by allowing automated closed-system inline testing technologies to perform critical clinical and commercial quality control activities. These developments are helping manufacturers move away from labor-intensive centralized production models while reducing release timelines for advanced therapies. As demand for personalized treatments continues to rise, automated and closed processing technologies are becoming essential for ensuring product consistency, scalability, and regulatory compliance.

Manufacturing Capacity Expansion Supporting Commercial Cell Therapy Growth

The automated and closed cell therapy processing systems market is benefiting from substantial investments in specialized manufacturing infrastructure. Legend Biotech expanded its Raritan, New Jersey facility, establishing one of the largest dedicated cell therapy manufacturing operations in the United States. The expanded site incorporates advanced automated processing technologies capable of supporting large-scale autologous production of CARVYKTI® for thousands of multiple myeloma patients annually. To preserve cell viability and product integrity throughout extraction, genetic modification, and formulation stages, the facility utilizes closed-loop processing assemblies that isolate patient-derived T cells from external cleanroom environments. This approach reduces contamination risks while improving process reproducibility and operational efficiency. As commercial demand for autologous cell therapies continues to increase, manufacturers are investing heavily in automated production systems that support higher throughput while maintaining stringent quality standards.

Global Investment Accelerating Closed-System Cell and Gene Therapy Manufacturing

The industry is also expanding geographically through significant investments in new cell and gene therapy manufacturing hubs. Bharat Biotech’s establishment of a dedicated cell and gene therapy production facility in Telangana demonstrates the growing global emphasis on advanced bioprocessing infrastructure. The facility incorporates single-use technologies and closed-system bioreactor cascades designed to meet international Good Manufacturing Practice requirements. These technologies enable efficient and scalable production while minimizing contamination risks and reducing operational complexity. The increasing adoption of automated, closed-system manufacturing platforms across global markets reflects the industry's focus on improving process control, reducing manual intervention, and supporting the commercial expansion of advanced cellular therapies. As regulatory agencies continue to support innovative manufacturing approaches, automated and closed processing systems are expected to remain central to the future development of cell and gene therapy production.

Automated and Closed Cell Therapy Processing Systems Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Automated and Closed Cell Therapy Processing Systems market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, Cytiva (Danaher Corporation), Thermo Fisher Scientific Inc., Sartorius AG, Terumo Corporation (Terumo BCT), Fresenius Kabi AG, Cellares Inc., MaxCyte, Inc., Cellular Origins (An Antleron company). The Automated and Closed Cell Therapy Processing Systems market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Automated and Closed Cell Therapy Processing Systems industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Automated and Closed Cell Therapy Processing Systems Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Automated and Closed Cell Therapy Processing Systems companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Automated and Closed Cell Therapy Processing Systems markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Automated and Closed Cell Therapy Processing Systems Market Competitive Benchmarking and Company Analysis

Leading companies in Automated and Closed Cell Therapy Processing Systems industry include- Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, Cytiva (Danaher Corporation), Thermo Fisher Scientific Inc., Sartorius AG, Terumo Corporation (Terumo BCT), Fresenius Kabi AG, Cellares Inc., MaxCyte, Inc., Cellular Origins (An Antleron company). The Automated and Closed Cell Therapy Processing Systems market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Automated and Closed Cell Therapy Processing Systems Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Automated and Closed Cell Therapy Processing Systems market remains one of the strongest-performing segments in the country.
The US Automated and Closed Cell Therapy Processing Systems Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Automated and Closed Cell Therapy Processing Systems market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Automated and Closed Cell Therapy Processing Systems industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Automated and Closed Cell Therapy Processing Systems markets

Canada's strong Automated and Closed Cell Therapy Processing Systems sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Automated and Closed Cell Therapy Processing Systems market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Automated and Closed Cell Therapy Processing Systems Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Automated and Closed Cell Therapy Processing Systems market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Automated and Closed Cell Therapy Processing Systems population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Automated and Closed Cell Therapy Processing Systems industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Automated and Closed Cell Therapy Processing Systems market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Automated and Closed Cell Therapy Processing Systems sales through 2034

France Automated and Closed Cell Therapy Processing Systems companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Automated and Closed Cell Therapy Processing Systems Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Automated and Closed Cell Therapy Processing Systems distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Automated and Closed Cell Therapy Processing Systems Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Automated and Closed Cell Therapy Processing Systems market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Automated and Closed Cell Therapy Processing Systems industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Automated and Closed Cell Therapy Processing Systems industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Automated and Closed Cell Therapy Processing Systems Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Automated and Closed Cell Therapy Processing Systems market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Automated and Closed Cell Therapy Processing Systems market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Automated and Closed Cell Therapy Processing Systems Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Automated and Closed Cell Therapy Processing Systems Market Segmentation

By Workflow
Apheresis
Separation
Expansion
Fill-Finish
Cryopreservation
By Product Type
Stem Cell Therapy Systems
Non-Stem Cell Therapy Systems
By Scale
Pre-commercial Scale
Commercial Scale
By End-User
Pharmaceutical & Biotechnology Companies
Hospitals & Academic Medical Centers
Contract Development & Manufacturing Organizations

Top Companies in Automated and Closed Cell Therapy Processing Systems Industry

Lonza Group AG
Miltenyi Biotec B.V. & Co. KG
Cytiva (Danaher Corporation)
Thermo Fisher Scientific Inc.
Sartorius AG
Terumo Corporation (Terumo BCT)
Fresenius Kabi AG
Cellares Inc.
MaxCyte, Inc.
Cellular Origins (An Antleron company)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025